A Phase 1 Study of MOR209/ES414 in Patients Wtih Metastatic Castration-Resistant Prostate Cancer
Phase of Trial: Phase I
Latest Information Update: 28 Jun 2017
At a glance
- Drugs MOR209-ES414 (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- Sponsors Aptevo Therapeutics; Emergent Product Development Seattle
- 10 Jun 2017 Biomarkers information updated
- 31 Mar 2017 According to an Aptevo Therapeutics media release, company has initiated protocol amendment in this trial to add continuous infusion of MOR209/ES414.
- 08 Sep 2015 According to MorphoSys media release, final clinical data expected in 2016.